Yara van Holstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yara van Holstein has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Simon P. Mooijaart
Department of Internal Medicine, Section of Gerontology and Geriatrics, University Medical Center Leiden, Leiden, The Netherlands
6 shared publicationsStella Trompet
Leiden Universitair Medisch Centrum, Department of Internal Medicine, Section Gerontology and Geriatrics , Zernikedreef 3 Leiden, Zuid Holland 2300 RC
5 shared publicationsDiana van Heemst
Department of Internal Medicine, section of Gerontology and Geriatrics, Leiden University Medical Center, the Netherlands
4 shared publicationsFrederiek van Den Bos
Department of Internal Medicine, section of Gerontology and Geriatrics, Leiden University Medical Center, the Netherlands
4 shared publications- Frederiek van Den Bos
Department of Internal Medicine, Section of Gerontology and Geriatrics, University Medical Center Leiden, Leiden, The Netherlands
4 shared publications - Nienke Aafke De Glas
Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
4 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by Springer Nature in Drugs & Aging
- Vol. 43 (8) , 733-743
The Association Between Anticholinergic Burden and Treatment-Related Complications in Older Adults with Cancer
Background Older adults constitute more than 50% of newly diagnosed cancer cases and polypharmacy is highly prevalent in this population. The Anticholinergic Burden (ACB) score quantifies the cumulative anticholinergic effects of all medications. Few studies link high ACB to adverse health outcomes in this population, and its effect on treatment outcomes remains largely unknown. Objective This study investigates the association between the ACB-score and treatment-related toxicity (grade ≥ 3), functional decline, and emergency room (ER) visits or hospitalization in older adults with cancer receiving chemotherapy and/or targeted therapy. Method Data from the Triage of Elderly Needing Treatment study were used and patients aged ≥ 70 years were included before start of chemotherapy and/or targeted therapy. Medication use was used to calculate the ACB score; ACB ≥ 3 was defined as high. The primary outcome was the association between ACB score and grade ≥ 3 toxicity. Associations were analyzed using univariable and multivariable logistic regression. Results 434 patients were included with a median age of 75.4 years; 56% were male and 15% had a high ACB-score. Grade ≥ 3 toxicity occurred more frequently in the high ACB group (OR 2.04, p = 0.013). In the multivariable model, ACB score and frailty were associated with grade ≥ 3 toxicity (OR 1.99, p = 0.022 and OR 1.79, p = 0.007). Conclusions High ACB is associated with poorer outcomes in older adults with cancer in addition to the known risk for toxicity of frailty.
- 22 July 2026
- Published by Springer Nature in Drugs & Aging
- Vol. 43 (8) , 733-743
Open AccessThe Association Between Anticholinergic Burden and Treatment-Related Complications in Older Adults with Cancer
Background Older adults constitute more than 50% of newly diagnosed cancer cases and polypharmacy is highly prevalent in this population. The Anticholinergic Burden (ACB) score quantifies the cumulative anticholinergic effects of all medications. Few studies link high ACB to adverse health outcomes in this population, and its effect on treatment outcomes remains largely unknown. Objective This study investigates the association between the ACB-score and treatment-related toxicity (grade ≥ 3), functional decline, and emergency room (ER) visits or hospitalization in older adults with cancer receiving chemotherapy and/or targeted therapy. Method Data from the Triage of Elderly Needing Treatment study were used and patients aged ≥ 70 years were included before start of chemotherapy and/or targeted therapy. Medication use was used to calculate the ACB score; ACB ≥ 3 was defined as high. The primary outcome was the association between ACB score and grade ≥ 3 toxicity. Associations were analyzed using univariable and multivariable logistic regression. Results 434 patients were included with a median age of 75.4 years; 56% were male and 15% had a high ACB-score. Grade ≥ 3 toxicity occurred more frequently in the high ACB group (OR 2.04, p = 0.013). In the multivariable model, ACB score and frailty were associated with grade ≥ 3 toxicity (OR 1.99, p = 0.022 and OR 1.79, p = 0.007). Conclusions High ACB is associated with poorer outcomes in older adults with cancer in addition to the known risk for toxicity of frailty.
- 28 November 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 54 (12)
The association between dispositional optimism and functioning and quality of life in older patients 12 months after cancer diagnosis: a multicentre cohort study
Background: The impact of cancer diagnosis and treatment on patients’ well-being is significant and personality traits such as optimism may play an important role in bearing difficulties and physical recovery. This study examined the association between dispositional optimism and changes in physical functioning and quality of life 12 months after cancer diagnosis. Methods: The study included patients aged ≥70 years with cancer before treatment initiation. Associations between dispositional optimism at baseline and a combined endpoint, defined as changes in physical functioning (ADL/IADL) or quality of life (EQ-5D/EQ-VAS) and/or mortality at 12 months were analysed using uni- and multivariable logistic regression. Results: We included 1,168 patients with a median age of 77 (IQR 73–82) years, of whom 49% were female. Screening with the Geriatric-8 showed risk of frailty in 75% of patients. Dispositional optimism, present in 70% of patients, was associated with preserved or improved IADL (OR 1.68, CI 1.22–2.31), EQ-5D (OR 1.72, CI 1.21–2.45) and EQ-VAS (OR 1.57, CI 1.11–2.23), and 7.2% lower mortality at 12 months. This was independent of age, gender, treatment intent, frailty, baseline functioning and quality of life. Conclusion: Dispositional optimism is associated with preserved or improved physical functioning and quality of life as well as reduced mortality 12 months after cancer diagnosis in older patients. Further research is needed to understand the role of optimism in coping with cancer, treatment, recovery and resilience which could lead to developing and evaluating interventions that increase optimism.
- 28 November 2025
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 54 (12)
The association between dispositional optimism and functioning and quality of life in older patients 12 months after cancer diagnosis: a multicentre cohort study
Background: The impact of cancer diagnosis and treatment on patients’ well-being is significant and personality traits such as optimism may play an important role in bearing difficulties and physical recovery. This study examined the association between dispositional optimism and changes in physical functioning and quality of life 12 months after cancer diagnosis. Methods: The study included patients aged ≥70 years with cancer before treatment initiation. Associations between dispositional optimism at baseline and a combined endpoint, defined as changes in physical functioning (ADL/IADL) or quality of life (EQ-5D/EQ-VAS) and/or mortality at 12 months were analysed using uni- and multivariable logistic regression. Results: We included 1,168 patients with a median age of 77 (IQR 73–82) years, of whom 49% were female. Screening with the Geriatric-8 showed risk of frailty in 75% of patients. Dispositional optimism, present in 70% of patients, was associated with preserved or improved IADL (OR 1.68, CI 1.22–2.31), EQ-5D (OR 1.72, CI 1.21–2.45) and EQ-VAS (OR 1.57, CI 1.11–2.23), and 7.2% lower mortality at 12 months. This was independent of age, gender, treatment intent, frailty, baseline functioning and quality of life. Conclusion: Dispositional optimism is associated with preserved or improved physical functioning and quality of life as well as reduced mortality 12 months after cancer diagnosis in older patients. Further research is needed to understand the role of optimism in coping with cancer, treatment, recovery and resilience which could lead to developing and evaluating interventions that increase optimism.
- Open Access
- 16 October 2024
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 15 (8) , 102075
Association of Glasgow Prognostic Score with frailty, mortality and adverse health outcomes in older patients with cancer: A prospective cohort study
- 16 October 2024
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 15 (8) , 102075
Open AccessAssociation of Glasgow Prognostic Score with frailty, mortality and adverse health outcomes in older patients with cancer: A prospective cohort study
- Open Access
- 4 July 2024
- Published by Springer Nature in GeroScience
- Vol. 46 (6) , 5615-5627
The performance of metabolomics-based prediction scores for mortality in older patients with solid tumors
Prognostic information is needed to balance benefits and risks of cancer treatment in older patients. Metabolomics-based scores were previously developed to predict 5- and 10-year mortality (MetaboHealth) and biological age (MetaboAge). This study aims to investigate the association of MetaboHealth and MetaboAge with 1-year mortality in older patients with solid tumors, and to study their predictive value for mortality in addition to established clinical predictors. This prospective cohort study included patients aged ≥ 70 years with a solid malignant tumor, who underwent blood sampling and a geriatric assessment before treatment initiation. The outcome was all-cause 1-year mortality. Of the 192 patients, the median age was 77 years. With each SD increase of MetaboHealth, patients had a 2.32 times increased risk of mortality (HR 2.32, 95% CI 1.59–3.39). With each year increase in MetaboAge, there was a 4% increased risk of mortality (HR 1.04, 1.01–1.07). MetaboHealth and MetaboAge showed an AUC of 0.66 (0.56–0.75) and 0.60 (0.51–0.68) for mortality prediction accuracy, respectively. The AUC of a predictive model containing age, primary tumor site, distant metastasis, comorbidity, and malnutrition was 0.76 (0.68–0.83). Addition of MetaboHealth increased AUC to 0.80 (0.74–0.87) (p = 0.09) and AUC did not change with MetaboAge (0.76 (0.69–0.83) (p = 0.89)). Higher MetaboHealth and MetaboAge scores were associated with 1-year mortality. The addition of MetaboHealth to established clinical predictors only marginally improved mortality prediction in this cohort with various types of tumors. MetaboHealth may potentially improve identification of older patients vulnerable for adverse events, but numbers were too small for definitive conclusions. The TENT study is retrospectively registered at the Netherlands Trial Register (NTR), trial number NL8107. Date of registration: 22–10-2019.
- 4 July 2024
- Published by Springer Nature in GeroScience
- Vol. 46 (6) , 5615-5627
Open AccessThe performance of metabolomics-based prediction scores for mortality in older patients with solid tumors
Prognostic information is needed to balance benefits and risks of cancer treatment in older patients. Metabolomics-based scores were previously developed to predict 5- and 10-year mortality (MetaboHealth) and biological age (MetaboAge). This study aims to investigate the association of MetaboHealth and MetaboAge with 1-year mortality in older patients with solid tumors, and to study their predictive value for mortality in addition to established clinical predictors. This prospective cohort study included patients aged ≥ 70 years with a solid malignant tumor, who underwent blood sampling and a geriatric assessment before treatment initiation. The outcome was all-cause 1-year mortality. Of the 192 patients, the median age was 77 years. With each SD increase of MetaboHealth, patients had a 2.32 times increased risk of mortality (HR 2.32, 95% CI 1.59–3.39). With each year increase in MetaboAge, there was a 4% increased risk of mortality (HR 1.04, 1.01–1.07). MetaboHealth and MetaboAge showed an AUC of 0.66 (0.56–0.75) and 0.60 (0.51–0.68) for mortality prediction accuracy, respectively. The AUC of a predictive model containing age, primary tumor site, distant metastasis, comorbidity, and malnutrition was 0.76 (0.68–0.83). Addition of MetaboHealth increased AUC to 0.80 (0.74–0.87) (p = 0.09) and AUC did not change with MetaboAge (0.76 (0.69–0.83) (p = 0.89)). Higher MetaboHealth and MetaboAge scores were associated with 1-year mortality. The addition of MetaboHealth to established clinical predictors only marginally improved mortality prediction in this cohort with various types of tumors. MetaboHealth may potentially improve identification of older patients vulnerable for adverse events, but numbers were too small for definitive conclusions. The TENT study is retrospectively registered at the Netherlands Trial Register (NTR), trial number NL8107. Date of registration: 22–10-2019.
- Open Access
- 13 July 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (7) , 101567
The association of blood biomarkers with treatment response and adverse health outcomes in older patients with solid tumors: A systematic review
- 13 July 2023
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 14 (7) , 101567
Open AccessThe association of blood biomarkers with treatment response and adverse health outcomes in older patients with solid tumors: A systematic review
- Open Access
Association of Biological Age with Tumor Microenvironment in Patients with Esophageal Adenocarcinoma
Biological age-related adaptations have been shown to modulate the non-malignant cells comprising the tumor microenvironment (TME). In the current work, we studied the association between biological age and TME characteristics in patients with esophageal adenocarcinoma. We comparatively assessed intratumoral histologic stroma quantity, tumor immune cell infiltrate, and blood leukocyte and thrombocyte count in 72 patients stratified in 3 strata of biological age (younger P = 0.022) relative to tumors in chronological-age-matched fit older adults. Moreover, in comparison to younger adults, frail older adults ( P = 0.032), but not fit older adults ( P = 0.302), demonstrated a lower blood thrombocyte count at the time of diagnosis. Lastly, we found an increased proportion of tumors with a histologic desert TME phenotype in frail older adults. Our findings provide a biological underpinning for the clinical relevance of assessing frailty in patients with esophageal adenocarcinoma, further justifying the need for standardized geriatric assessment in geriatric cancer patients.
Open AccessAssociation of Biological Age with Tumor Microenvironment in Patients with Esophageal Adenocarcinoma
Biological age-related adaptations have been shown to modulate the non-malignant cells comprising the tumor microenvironment (TME). In the current work, we studied the association between biological age and TME characteristics in patients with esophageal adenocarcinoma. We comparatively assessed intratumoral histologic stroma quantity, tumor immune cell infiltrate, and blood leukocyte and thrombocyte count in 72 patients stratified in 3 strata of biological age (younger P = 0.022) relative to tumors in chronological-age-matched fit older adults. Moreover, in comparison to younger adults, frail older adults ( P = 0.032), but not fit older adults ( P = 0.302), demonstrated a lower blood thrombocyte count at the time of diagnosis. Lastly, we found an increased proportion of tumors with a histologic desert TME phenotype in frail older adults. Our findings provide a biological underpinning for the clinical relevance of assessing frailty in patients with esophageal adenocarcinoma, further justifying the need for standardized geriatric assessment in geriatric cancer patients.
- Open Access
- 23 February 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (4) , 459-467
Geriatric assessment and treatment outcomes in a Dutch cohort of older patients with potentially curable esophageal cancer
Patients with potentially curable esophageal cancer can be treated with neo-adjuvant chemoradiotherapy followed by surgery or definitive chemoradiotherapy with curative intent. For frail older pati...
- 23 February 2022
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 61 (4) , 459-467
Open AccessGeriatric assessment and treatment outcomes in a Dutch cohort of older patients with potentially curable esophageal cancer
Patients with potentially curable esophageal cancer can be treated with neo-adjuvant chemoradiotherapy followed by surgery or definitive chemoradiotherapy with curative intent. For frail older pati...
- Open Access
- 30 June 2021
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 28 (6) , 852-859
Functional Performance After Complex Endovascular Aortic Repair: A Single-Center Retrospective Cohort Study
Complex endovascular aortic repair (EVAR) procedures provide a treatment option for patients with aortic aneurysms involving visceral branches. Good technical results and short-term outcomes have been reported. Whether complex EVAR provides acceptable functional outcomes is not clear. The current study aims to describe postoperative functional outcomes in complex EVAR patients—an older and relatively frail patient group. A single-center retrospective cohort study was performed, using data from a computerized database of consecutive patients who underwent complex EVAR in the Leiden University Medical Center (LUMC, The Netherlands) between July 2013 and September 2020. As of May 2017, patients scheduled for complex EVAR were referred to a geriatric care pathway to determine (Instrumental) Activities of Daily Living ((I)ADL) scores at baseline and, if informed consent was given, after 12 months. For the total patient group, adverse functional performance outcomes were: discharge to a nursing home and 12-month mortality. For the patients included in geriatric follow-up, the additional outcome was the incidence of functional decline (defined by a ≥2 point increase in (I)ADL-score) at 12-month follow-up Eighty-two patients underwent complex EVAR, of which 68 (82.9%) were male. Mean age was 73.3 years (SD=6.3). Within 30 days postsurgery, 6 patients (7.3%) died. Mortality within 12 months for the total patient group was 14.6% (n=12). After surgery, no patients had to be discharged to a nursing home. Fifteen patients (18.3%) were discharged to a rehabilitation center. Twenty-three patients gave informed consent and were included in geriatric follow-up. Five patients (21.7%) presented functional decline 12 months postsurgery and 4 patients had died (17.4%) by that time. This means that 39.1% of the patients in the care pathway suffered an adverse outcome. To our knowledge, this is the only study that examined functional performance after complex EVAR, using a prospectively maintained database. No patients were newly discharged to a nursing home and functional performance results at 12 months are promising. Future multidisciplinary research should focus on determining which patients are most prone to deterioration of function, so that efforts can be directed toward preventing postoperative functional decline.
- 30 June 2021
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 28 (6) , 852-859
Open AccessFunctional Performance After Complex Endovascular Aortic Repair: A Single-Center Retrospective Cohort Study
Complex endovascular aortic repair (EVAR) procedures provide a treatment option for patients with aortic aneurysms involving visceral branches. Good technical results and short-term outcomes have been reported. Whether complex EVAR provides acceptable functional outcomes is not clear. The current study aims to describe postoperative functional outcomes in complex EVAR patients—an older and relatively frail patient group. A single-center retrospective cohort study was performed, using data from a computerized database of consecutive patients who underwent complex EVAR in the Leiden University Medical Center (LUMC, The Netherlands) between July 2013 and September 2020. As of May 2017, patients scheduled for complex EVAR were referred to a geriatric care pathway to determine (Instrumental) Activities of Daily Living ((I)ADL) scores at baseline and, if informed consent was given, after 12 months. For the total patient group, adverse functional performance outcomes were: discharge to a nursing home and 12-month mortality. For the patients included in geriatric follow-up, the additional outcome was the incidence of functional decline (defined by a ≥2 point increase in (I)ADL-score) at 12-month follow-up Eighty-two patients underwent complex EVAR, of which 68 (82.9%) were male. Mean age was 73.3 years (SD=6.3). Within 30 days postsurgery, 6 patients (7.3%) died. Mortality within 12 months for the total patient group was 14.6% (n=12). After surgery, no patients had to be discharged to a nursing home. Fifteen patients (18.3%) were discharged to a rehabilitation center. Twenty-three patients gave informed consent and were included in geriatric follow-up. Five patients (21.7%) presented functional decline 12 months postsurgery and 4 patients had died (17.4%) by that time. This means that 39.1% of the patients in the care pathway suffered an adverse outcome. To our knowledge, this is the only study that examined functional performance after complex EVAR, using a prospectively maintained database. No patients were newly discharged to a nursing home and functional performance results at 12 months are promising. Future multidisciplinary research should focus on determining which patients are most prone to deterioration of function, so that efforts can be directed toward preventing postoperative functional decline.
- Open Access
- 7 January 2021
- Published by Springer Nature in BMC Geriatrics
- Vol. 21 (1) , 1-10
Design and rationale of a routine clinical care pathway and prospective cohort study in older patients needing intensive treatment
Background: Treatment decisions concerning older patients can be very challenging and individualised treatment plans are often required in this very heterogeneous group. In 2015 we have implemented a routine clinical care pathway for older patients in need of intensive treatment, including a comprehensive geriatric assessment (CGA) that was used to support clinical decision making. An ongoing prospective cohort study, the Triaging Elderly Needing Treatment (TENT) study, has also been initiated in 2016 for participants in this clinical care pathway, to study associations between geriatric characteristics and outcomes of treatment that are relevant to older patients. The aim of this paper is to describe the implementation and rationale of the routine clinical care pathway and design of the TENT study. Methods: A routine clinical care pathway has been designed and implemented in multiple hospitals in the Netherlands. Patients aged ≥70 years who are candidates for intensive treatments, such as chemotherapy, (chemo-)radiation therapy or major surgery, undergo frailty screening based on the Geriatric 8 (G-8) questionnaire and the Six-Item Cognitive Impairment Test (6CIT). If screening reveals potential frailty, a CGA is performed. All patients are invited to participate in the TENT study. Clinical data and blood samples for biomarker studies are collected at baseline. During follow-up, information about treatment complications, hospitalisations, functional decline, quality of life and mortality is collected. The primary outcome is the composite endpoint of functional decline or mortality at 1 year. Discussion: Implementation of a routine clinical care pathway for older patients in need of intensive treatment provides the opportunity to study associations between determinants of frailty and outcomes of treatment. Results of the TENT study will support individualised treatment for future patients. Trial registration: The study is retrospectively registered at the Netherlands Trial Register (NTR), trial number NL8107. Date of registration: 22-10-2019.
- 7 January 2021
- Published by Springer Nature in BMC Geriatrics
- Vol. 21 (1) , 1-10
Open AccessDesign and rationale of a routine clinical care pathway and prospective cohort study in older patients needing intensive treatment
Background: Treatment decisions concerning older patients can be very challenging and individualised treatment plans are often required in this very heterogeneous group. In 2015 we have implemented a routine clinical care pathway for older patients in need of intensive treatment, including a comprehensive geriatric assessment (CGA) that was used to support clinical decision making. An ongoing prospective cohort study, the Triaging Elderly Needing Treatment (TENT) study, has also been initiated in 2016 for participants in this clinical care pathway, to study associations between geriatric characteristics and outcomes of treatment that are relevant to older patients. The aim of this paper is to describe the implementation and rationale of the routine clinical care pathway and design of the TENT study. Methods: A routine clinical care pathway has been designed and implemented in multiple hospitals in the Netherlands. Patients aged ≥70 years who are candidates for intensive treatments, such as chemotherapy, (chemo-)radiation therapy or major surgery, undergo frailty screening based on the Geriatric 8 (G-8) questionnaire and the Six-Item Cognitive Impairment Test (6CIT). If screening reveals potential frailty, a CGA is performed. All patients are invited to participate in the TENT study. Clinical data and blood samples for biomarker studies are collected at baseline. During follow-up, information about treatment complications, hospitalisations, functional decline, quality of life and mortality is collected. The primary outcome is the composite endpoint of functional decline or mortality at 1 year. Discussion: Implementation of a routine clinical care pathway for older patients in need of intensive treatment provides the opportunity to study associations between determinants of frailty and outcomes of treatment. Results of the TENT study will support individualised treatment for future patients. Trial registration: The study is retrospectively registered at the Netherlands Trial Register (NTR), trial number NL8107. Date of registration: 22-10-2019.
- Open Access
- 18 July 2019
- Published by Springer Nature in Drugs & Aging
- Vol. 36 (10) , 927-938
Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
The number of older patients with cancer is increasing as a result of the ageing of Western societies. Immune checkpoint inhibitors have improved cancer treatment and are associated with lower rates of treatment-related toxicity compared with chemotherapy in the general population. Nonetheless, immune checkpoint inhibitors have potentially serious immune-related adverse events, which might have a greater impact on older and more vulnerable patients and potentially influence treatment efficacy and quality of life. Previous clinical trials have shown no major increase in immune-related adverse events; however, older patients are underrepresented and relatively healthy in these trials. Observational studies suggest that older and more vulnerable patients may be at a higher risk of immune-related adverse events and early treatment discontinuation. Geriatric assessment could help identify older patients who will benefit from immune checkpoint inhibitors.
- 18 July 2019
- Published by Springer Nature in Drugs & Aging
- Vol. 36 (10) , 927-938
Open AccessEfficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
The number of older patients with cancer is increasing as a result of the ageing of Western societies. Immune checkpoint inhibitors have improved cancer treatment and are associated with lower rates of treatment-related toxicity compared with chemotherapy in the general population. Nonetheless, immune checkpoint inhibitors have potentially serious immune-related adverse events, which might have a greater impact on older and more vulnerable patients and potentially influence treatment efficacy and quality of life. Previous clinical trials have shown no major increase in immune-related adverse events; however, older patients are underrepresented and relatively healthy in these trials. Observational studies suggest that older and more vulnerable patients may be at a higher risk of immune-related adverse events and early treatment discontinuation. Geriatric assessment could help identify older patients who will benefit from immune checkpoint inhibitors.